Esperion Therapeutics, Inc. (ESPR) Receives $19.71 Average Price Target from the Analysts
- Author: Zachary Reyes Feb 24, 2017,
Feb 24, 2017, 15:12
The stock's quarterly performance indicates a Positive momentum of 95.74 percent, whereas its last one month trend is Optimistic with 105.38 percent. Let us view how analysts have ranked ESPR in recent few months. Stifel Nicolaus reaffirmed a "buy" rating and issued a $64.00 price target on shares of Esperion Therapeutics in a research note on Thursday, September 22nd.
11/06/2015 - Esperion Therapeutics, Inc. had its "buy" rating reiterated by analysts at Bank of America Merrill Lynch. Citigroup Inc. lowered shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research note on Monday, November 14th. Finally, JMP Securities reaffirmed a "buy" rating on shares of Esperion Therapeutics in a research note on Sunday, November 6th.
Considering the performance, Esperion Therapeutics, Inc. The stock price is up +62.1% over the past year.
Rent-A-Center operates company owned rent-to-own stores which offer high-quality, durable goods such as consumer electronics, appliances, furniture and accessories to consumers under flexible rental purchase arrangements that allow the customer to obtain ownership of the merchandise at the conclusion of an agreed-upon rental period. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. ColorTyme, Inc., a wholly-owned subsidiary of the Company, is a national franchisor of rent-to-own stores, which operate under the trade name of "ColorTyme", and under the "Rent-A-Center" name.
Large investors have recently added to or reduced their stakes in the stock. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.24) by $0.05. Elkfork Partners LLC purchased a new stake in Esperion Therapeutics during the fourth quarter valued at $169,000. BlackRock Institutional Trust Company N.A. now owns 352,706 shares of the biopharmaceutical company's stock valued at $3,485,000 after buying an additional 21,756 shares during the last quarter.
Esperion had approximately 22.6 million shares of common stock outstanding, with another 3.5 million issuable upon exercise of stock options and warrants and vesting of restricted stock units, and $2.7 million of debt outstanding as of December 31, 2016. Dimensional Fund Advisors LP owned about 0.18% of Esperion Therapeutics worth $504,000 at the end of the most recent quarter.
Shares of Esperion Therapeutics (NASDAQ:ESPR) opened at 12.52 on Wednesday. The price is now 14.6% above its 50-day moving average and -21.21% below its 200-day moving average.
Also covering Esperion Therapeutics's price target, a total of 12 equity analysts have released a ratings update on ESPR. The firm's market capitalization is $526.45 million. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has a current Value Composite Score of 76. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.82) by $0.05. During the same period in the previous year, the business posted ($0.58) EPS.
The decrease in general and administrative expenses was primarily related to a reduction in pre-commercialization activities, partially offset by increases in costs to support public company operations, increases in the Company's headcount, and other costs to support Esperion's growth. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to treat patients with hypercholesterolemia whose LDL-C is not adequately controlled with low- and moderate-dose statins.